Driver MutationsNon-small Cell Lung Cancer (NSCLC) has become the most prominent example demonstrating the importance of targeted therapy in cancer treatment. Up to 25% of patients with non-squamous NSCLC (nsNSCLC) harbor driver mutations which are responsible for the malignancy. For these patient...
Driver mutations in non-small cell lung cancer (NSCLC) have a relevant significance for clinical management. EGFR mutations are the most important predictive biomarkers for NSCLC, although KRAS and BRAF mutations can also be prognostic and predictive biomarkers, respectively. PCR-based approaches ...
mutations in 341 cancer-associated genes as a function of BMI, focusing on gene–cancer type pairs with sufficient numbers of mutant patients for adequate statistical power (Methods). Considering only oncogenic mutations as annotated by a Food and Drug Administration-recognized database9, we ...
Osimertinib is the preferred option for EGFR mutations. New Driver Alterations: The guidelines now include recommendations for emerging targets like MET and RET, reflecting the evolving landscape of molecular profiling in NSCLC. Combination Therapy Strategies: Research into combining targeted therapies ...
Somatic mutations in the EGFR gene play key roles in determining the sensitivity of NSCLC patients treated with EGFR inhibitor drugs; however, most of the patients who respond to EGFR kinase inhibitors are the adenocarcinoma subtype of NSCLC [7]. In contrast, patients with the lung squamous cell...
Missense driver mutations in cancer are concentrated in a few hotspots1. Various mechanisms have been proposed to explain this skew, including biased mutational processes2, phenotypic differences3–6 and immunoediting of neoantigens7,8; however, to our k
As a typical example of drug resistance, gefitinib is a small-molecule ATP-competitive reversible EGFR inhibitor used in the clinic for the treatment of advanced NSCLC harboring EGFR-activating mutations. After an initial response, the tumors invariably relapse, in half of the cases because of the...
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide [1]. NSCLC, and lung adenocarcinoma in particular, is frequently associated with oncogenic driver mutations. The representative oncogenic driver mutations in NSCLC are found in EGFR, KRAS, and ALK fusion ...
Laying the Groundwork to Confront the Final Frontier of CNS Metastasis in NSCLC with Targetable Driver Mutations 来自 Elsevier 喜欢 0 阅读量: 27 作者: Thanyanan Reungwetwattana,Sai-Hong Ignatius Ou DOI: 10.1016/j.jtho.2016.01.005 年份: 2016 ...
PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies Oncotarget, 6 (2) (2015), pp. 1315-1326 Google Scholar [37] L. Huang, L. Fu Mechanisms of resistance to EGFR tyrosine kinase inhibitors Acta Pharm. Sin. B,...